A phase II clinical trial of the RAGE inhibitor TTP488 targeting mild-to-moderate AD patients was also associated with improved cognitive function as assessed by Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) (68). This evidence concerns the gene AGER and Alzheimer disease.